Sage Therapeutics’ dalzanemdor, formerly known as SAGE-718, an investigational oral medication for mild cognitive impairment (MCI) due to Parkinson’s disease, has failed to outperform a placebo in a Phase 2 study. Based on these top-line data from the trial, called PRECEDENT (NCT05318937), Sage will stop any further…
Updated exercise guidelines for those with Parkinson’s disease released by The Michael J. Fox Foundation (MJFF) now include Nordic pole walking as a suggested aerobic activity to help mitigate symptoms and improve everyday life. The exercise, a Finnish-derived low-impact total body walk, is also known as urban…
Having irritable bowel syndrome (IBS), a gastrointestinal disorder that may be linked to how the brain and gut communicate with each other, does not seem to increase a person’s risk for Parkinson’s disease, according to a new study of more than 400,000 people. In an analysis, the researchers “did…
Three biobehavioral scientists at Teachers College (TC), Columbia University are working on separate collaborative efforts in exercise, speech, and swallowing among Parkinson’s patients to potentially improve quality of life for the more than 10 million people estimated globally to be living with the progressive neurodegenerative disease. In honor…
The estate of a longtime supporter of the Norton Neuroscience Institute at Norton Healthcare has gifted the center $20 million to help expand programming and research in Parkinson’s disease and other movement disorders. The donation from the estate of Elizabeth Pahk Cressman, MD, PhD, will aid the Louisville,…
Cycling indoors on a stationary bicycle for two may improve the health and well-being of people with Parkinson’s disease and their care partners, a preliminary small study at the University of South Carolina suggests. The results were presented at the annual meeting of the American Academy of Neurology, which…
ND0612, a formation of levodopa/carbidopa administered continuously by an under-the-skin pump, led to better symptom control for people with advanced Parkinson’s disease in a Phase 3 trial, and the therapy’s efficacy and safety were consistent irrespective of patient factors like age, weight, and medication dosage. That’s according to…
TreeFrog Therapeutics’ investigational cell therapy restored motor function in a rat model of Parkinson’s disease, according to a recent presentation. The therapy, designed to replace the dopamine-producing nerve cells lost in Parkinson’s, involves transplanting a three-dimensional “microtissue” that contains the cells directly into the brain. Kevin Alessandri, PhD,…
The Syn-One test, which uses a skin biopsy to look for atypical clumps of the protein alpha-synuclein, may help both in confirming a diagnosis and guiding treatment decisions for people being evaluated for Parkinson’s disease, new data show. “Skin biopsies are minimally invasive and, our study showed, very effective…
AB-1005, an experimental gene therapy administered directly into the brain, helped ease motor symptoms in patients with moderate Parkinson’s disease, whereas it appeared to stabilize disease progression for those with mild disease in a small Phase 1 clinical trial. No serious safety issues were reported for the 11…
Get regular updates to your inbox.
